Search Results
Your search for world matches 4350 pages
Showing 4201 - 4250Expert Point of View: Vincent Grégoire, MD, PhD
After presentation of the study by Cheng and colleagues at the 2015 European Cancer Congress, formal discussant Vincent Grégoire, MD, PhD, Department of Radiation Oncology, UCL St-Luc University Hospital, Brussels, Belgium, was cautious in endorsing a surgical approach for stage III and IV...
V. Craig Jordan, OBE, PhD, DSc, FMedSci, Receives Sir James Black Award
V. Craig Jordan, OBE, PhD, DSc, FMedSci, a breast cancer research pioneer known for his development of the therapeutic drug tamoxifen, has been named a recipient of the Sir James Black Award from the British Pharmacological Society. Dr. Jordan, Professor in the Department of Breast Medical...
Friends of Cancer Research Releases White Paper on Patient-Reported Outcomes
On November 17, Friends of Cancer Research (FOCR) released a white paper report, Enhancing Use of Patient-Centered Data in Regulatory Decision Making.1 The contents of that paper are summarized below. Improving Patient Input Many stakeholders agree that to ensure truly transformational therapies,...
Clinical Trial System Badly in Need of Overhaul, Say Panelists at Friends-Brookings Conference
Cancer clinical trials in three distinct phases, as they have been conducted for decades, are probably no longer the best way to bring a drug or biologic agent to market. This was the consensus of three panels at the 8th Annual Conference on Clinical Cancer Research convened by Friends of Cancer...
Breast Cancer Survivors May Expect More Extensive or Frequent Follow-up Testing Than Recommended
Patients who have been treated for breast cancer may overestimate the value of follow-up testing and may expect—or even ask for—more testing than recommended, Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Harvard Medical School, Boston, told participants at the Lynn Sage...
St. Jude Names Carlos Rodriguez-Galindo, MD, Director of International Outreach Program
Carlos Rodriguez-Galindo, MD, an international leader in pediatric solid tumor research, is joining St. Jude Children’s Research Hospital to head the International Outreach Program. Dr. Rodriguez-Galindo will serve as International Outreach Program Director and an executive vice president. He will...
ASCO and AAHPM Define Primary Palliative Care in Oncology
A new guidance statement from ASCO and the American Academy of Hospice and Palliative Medicine (AAHPM) could potentially lead to more standardized primary palliative care delivery across oncology settings, according to Kathleen E. Bickel, MD, MPhil, who presented the study findings at the 2015...
Study Reports Improved Survival With Lapatinib and CapeOx in Asian and Younger Patients With HER2-Positive Advanced Gastroesophageal Adenocarcinoma
In a phase III trial (TRIO-013/LOGiC) reported in the Journal of Clinical Oncology, Hecht et al found that the addition of lapatinib (Tykerb) to capecitabine-oxaliplatin (CapeOx) in patients with previously untreated HER2-amplified advanced gastroesophageal adenocarcinoma did not improve overall...
ESMO Asia 2015: Cancer Drives Patients to Poverty in Southeast Asia
Five percent of cancer patients and their families were pushed into poverty in Southeast Asia between March 2012 and September 2013 because of high disease-related costs, a study (Abstract 52O) by Bhoo-Pathy et al at the European Society for Medical Oncology (ESMO) Asia 2015 Congress in Singapore...
Bruce E. Johnson, MD, FASCO, Elected ASCO President for 2017–2018 Term
Bruce E. Johnson, MD, FASCO, has been elected President of ASCO for the term beginning in June 2017. He will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2016. Additionally, four new members were elected to the ASCO Board of Directors, as well as three new...
New ‘Condensed’ Grading System Shown to Be Accurate for Predicting Prostate Cancer Outcomes
Using information gleaned from more than 20,000 men, researchers at Johns Hopkins have affirmed the value of their alternative system for assessing the likelihood of growth and spread of prostate cancer. The new grading system, they said, is not only easier to use and understand, but also more...
Researchers Develop Mathematical Model to Forecast Metastatic Breast Cancer Survival Rates
University of Southern California (USC) researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting, and surfing the Web. For decades, medical schools have taught doctors that...
Self-Reported Fatigue Provides Independent Prognostic Information in Patients With Myelodysplastic Syndromes
In a prospective observational cohort study reported in The Lancet Oncology, Efficace et al found that a self-reported fatigue score provides independent prognostic information on overall survival in patients with higher-risk myelodysplastic syndromes. Fatigue assessment should be included in...
Anemia Prevalent and Independently Associated With Functional Disability in Older Patients With Cancer
“Anemia was highly prevalent and independently associated with functional disability” among older adults with cancer, according to an analysis of data conducted by Owusu et al. “Older patients with anemia were more than twice as likely to have functional disability than those...
Reported Hospitalization Rate in Patients Receiving Systemic Therapy for Metastatic NSCLC Much Higher in Real-World vs Clinical Trial Setting
In a study reported in JAMA Oncology, Prince et al found that the hospitalization rate among patients receiving systemic therapy for metastatic non–small cell lung cancer (NSCLC) was much higher in observational studies vs clinical trials among studies reporting hospitalization rates. Study...
ABC3: Experts Create New Consensus Guidelines for Advanced Breast Cancer Treatment
Although advanced breast cancer is incurable, there are some patients who have just a few small metastases who would respond well to systemic treatments such as chemotherapy and hormone therapy. In new guidelines agreed on by participants at the Advanced Breast Cancer Third International Consensus...
Experimental Drug Shown to Prevent Neuroblastoma in Preclinical Study
Australian scientists have identified a critical molecular “feedback loop” that helps initiate and drive neuroblastoma, a cancer of the nervous system in children that is triggered in embryonal nerve cells. This feedback loop massively accelerates cancer development. The research team...
ASTRO 2015: Pediatric Patients With Ependymoma Have Favorable Outcomes With Immediate Postsurgical Radiation Therapy
Outcomes for pediatric patients as young as 12 months old with ependymoma who are treated with immediate postoperative radiation therapy are favorable and consistent, based upon tumor surgical resection and tumor grade, according to research presented by Merchant et al (Abstract 1) on October...
ASTRO 2015: Patients With Intermediate-Risk Meningiomas Who Receive Postoperative Radiotherapy Have a 96% 3-Year Progression-Free Survival
Patients with intermediate meningiomas treated with radiation therapy after surgery experienced a 96% 3-year progression-free survival rate and had minimal adverse events, according to research presented by Rogers et al October 21, 2015, at the American Society for Radiation Oncology’s...
Similar Pain Outcome With Ibandronate vs Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer
In a UK phase III noninferiority trial reported in the Journal of the National Cancer Institute, Hoskin et al found similar effects of single-dose ibandronate and single-dose radiotherapy on localized metastatic bone pain in patients with prostate cancer. Study Details In the open-label trial,...
ECC 2015: Tackling the Global Shortfall in Radiotherapy
Millions of people are unable to receive necessary treatment worldwide because of a chronic underinvestment in radiotherapy resources, according to a major new Commission on access to radiotherapy, published in by Atun et al in The Lancet Oncology, and presented at the 2015 European Cancer Congress ...
ECC 2015: Discovery of Differences Between Tumors of Younger and Older Patients With Colorectal Cancer May Lead to Better Treatments
Colorectal cancer is on the rise among younger patients. Although some of the younger-onset cases can be explained by hereditary factors, the majority arise spontaneously. Researchers have now found that tumors in younger patients with colorectal cancer may be molecularly distinct from those of...
ECC 2015: Hormone Therapy May Prevent Ovarian Failure and Preserve Fertility in Women With Breast Cancer
Young women undergoing chemotherapy for breast cancer may be more likely to remain fertile if they also receive hormonal treatment, according to new research (Abstract 1957) presented at the 2015 European Cancer Congress in Vienna, Austria, and published simultaneously by Lambertini et al in Annals ...
ECC 2015: Over Three-Quarters of People With Cancer Worldwide Have No Access to Safe Surgery
Over 80% of the 15 million people diagnosed with cancer worldwide in 2015 will need surgery, but less than one-quarter of them will have access to proper, safe, affordable surgical care when they need it, according to a major new Commission examining the state of global cancer surgery. The...
ECC 2015: EUROCARE Results Show Large Variations in Survival Among European Countries
Comparisons of cancer patients’ survival and care in Europe up to 2007 showed that although more patients are surviving for at least 5 years after diagnosis, there are large variations among countries, which are particularly significant in cancers of the blood. Milena Sant, MD, from the...
Patient Characteristics in Trials of Targeted Therapies for Metastatic Renal Cell Carcinoma Differ From Those in Real-World Population
Patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in real-world clinical practice tend to be older and sicker than the patients enrolled in pivotal clinical trials of tyrosine kinase inhibitors. Conversely, patients with metastatic renal cell carcinoma treated...
Internationally Acclaimed Cancer Researcher, Gianni Bonadonna, MD, Dies at 81
Gianni Bonadonna, MD, was considered the “Father of Italian Oncology,” but his scientific contributions to the field and his generous collegial spirit extended far beyond the shores of his native land. Dr. Bonadonna was at the forefront in the battle to convince the surgical...
WCLC: Cetuximab May Improve Survival in Some Patients With EGFR-Positive Squamous NSCLC
Analysis of a large phase III trial (S0819) suggested that adding the epidermal growth factor receptor (EGFR)-targeting monoclonal antibody cetuximab (Erbitux) to chemotherapy benefits survival in patients with squamous cell non–small cell lung cancer (NSCLC) with tumors positive...
WCLC: New Study Reveals Genomic Architecture of EGFR Mutations in Lung Cancer
Epidermal growth factor receptor (EGFR) mutations are one of the most common driver oncogenes in lung cancer, typified by high response rates when treated with tyrosine kinase inhibitors and median progression-free survival of 10 months, commonly due to emergence of T790M. The genomic...
WCLC: Effect of EGFR Protein and EGFR Gene Copy Number in SQUIRE Trial
Previously, researchers reporting on the SQUIRE study demonstrated that the addition of necitumumab to gemcitabine-cisplatin improved overall survival in patients with stage IV squamous non–small cell lung cancer (NSCLC). Following up on these findings, Fred R. Hirsch, MD, PhD,...
WCLC: Adding Bevacizumab to Chemotherapy Does Not Improve Overall Survival in Early-Stage NSCLC
Adding the monoclonal antibody bevacizumab (Avastin) to chemotherapy for patients with surgically removed non–small cell lung cancer (NSCLC) did not improve overall survival, according to research (Abstract PLEN04.03) presented at the 16th World Conference on Lung Cancer (WCLC) in Denver,...
WCLC: Smoking Cessation Reduces Mortality in Low-Dose Computed Tomography Screening Volunteers
Smoking cessation among patients enrolled in a low-dose computed tomography screening program is associated with a three- to five-time reduction in mortality, according to research (Abstract PLEN04.07) presented at the 16th World Conference on Lung Cancer (WCLC) in Denver, Colorado. The Conference...
WCLC: Results From ROMANA Trials of Anamorelin in Advanced NSCLC Patients With Cachexia
Two phase III studies of anamorelin found that the medication effectively combats wasting and increases body weight and lean body mass in certain patients with lung cancer. Results (Abstract ORAL29.01) from the ROMANA 1 and ROMANA 2 phase III trials of anamorelin were presented at the 16th...
WCLC: IASLC Issues Statement on Tobacco Control and Smoking Cessation
The International Association for the Study of Lung Cancer (IASLC) issued a new statement on Tobacco Control and Smoking Cessation on September 7 at the 16th World Conference on Lung Cancer (WCLC) in Denver, Colorado. The statement calls for higher taxes on tobacco products; comprehensive...
WCLC: Bevacizumab Plus Standard Chemotherapy Improves Survival in Mesothelioma
The standard of care for malignant pleural mesothelioma may be poised for change, judging by results from a study (Abstract ORAL11.01) by the French Cooperative Thoracic Intergroup. The addition of bevacizumab (Avastin) in the first-line setting to the current standard of care, pemetrexed...
WCLC: Impact of Time to Drug Approval on Potential Years of Life Lost
Every hour lost to the cancer drug regulatory process costs 29 life-years lost in the United States and 260 life-years worldwide, according to research (Abstract ORAL12.05) presented on September 7 at the 16th World Conference on Lung Cancer hosted by the International Association of the...
Malaria-Causing Parasite May Contribute to Development of Burkitt Lymphoma
In an equatorial African region known as the “lymphoma belt,” children are ten times more likely than in other parts of the world to develop Burkitt lymphoma. This area is also plagued by high rates of malaria, and scientists have spent the past 50 years trying to understand how the two ...
Intraperitoneal Plus Intravenous Chemotherapy—an Underused Strategy—May Improve Survival in Advanced Ovarian Cancer
An observational study investigating the use and effectiveness of a combination regimen of intraperitoneal and intravenous chemotherapy in the treatment of advanced-stage ovarian cancer has found that although the dual approach substantially improved survival—81% of those treated with the...
ESMO World GI 2015: Second-Line Cetuximab Active Beyond Progression in Metastatic Colorectal Cancer
Patients with metastatic colorectal cancer that are free of mutations in the KRAS, NRAS, BRAF, and PIK3CA genes showed a significant benefit from continuing antiepidermal growth factor receptor (EGFR) therapy beyond progression following first-line chemotherapy and an anti-EGFR monoclonal antibody. ...
ESMO World GI 2015: Studies Confirm Regorafenib Benefit in Pretreated Metastatic Colorectal Cancer
The phase IIIb CONSIGN trial has confirmed the benefit of regorafenib (Stivarga) in patients with previously treated metastatic colorectal cancer, researchers announced July 3 at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer in Barcelona, Spain (Abstract...
Dutch Study Indicates No Survival Benefit of Adding Metformin to Gemcitabine-Erlotinib in Advanced Pancreatic Cancer
In a Dutch phase II study reported in The Lancet Oncology, Kordes et al found that adding metformin to gemcitabine-erlotinib (Tarceva) did not improve overall survival in patients with advanced pancreatic cancer. Study Details In the double-blind study, 121 patients from four centers in the...
ESMO World GI 2015: SENRI Trial Evaluates NK1 Antagonists for Emesis Prevention in Oxaliplatin-Based Chemotherapy
The SENRI trial has opened the window to evaluate neurokinin 1 (NK1) antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, said European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO) spokesperson and antiemetics expert Fausto Roila, MD....
ESMO World GI 2015: Low Body Mass Index Associated With Poorer Survival in Metastatic Colorectal Cancer
Although being overweight with a high body mass index (BMI) has long been associated with a higher risk for colorectal cancer, thinner patients might not fare as well as previously expected after treatment for advanced cancer, according to a new study from Duke Medicine. The study, which was...
Assay Permits Rapid Molecular Characterization of Glioma
As reported in JAMA Oncology, Shankar et al developed a rapid genotyping assay to detect single nucleotide variants in telomerase reverse transcriptase (TERT) promoter and isocitrate dehydrogenase 1 (IDH1) genes that may assist in intraoperative decisions to perform definitive neurosurgical...
Multicenter Study Redefines Brain Tumor Diagnosis and Treatment
Scientists at multiple institutions have found a new way of classifying brain cancers that could very well change how the illness is diagnosed and treated. The study, a project of The Cancer Genome Atlas, found striking molecular differences between various forms of gliomas by looking at the makeup ...
Livers Donated After Cardiac Death Are Safe to Use in Liver Cancer Patients
In the largest study of its kind, transplant physicians at Mayo Clinic in Florida have found that liver cancer patients have similar beneficial outcomes whether using organs donated by patients after cardiac death or brain death. The study was recently published by Croome et al in the American...
Analysis Shows New Cancer Cases Rise Globally, but Death Rates Decline in Many Countries
New cases of virtually all types of cancer are rising in countries globally—regardless of income—but the death rates from cancer are falling in many countries, according to a new analysis of 28 cancer groups in 188 countries. These findings were published by Fitzmaurice et al in JAMA...
ASCO 2015: First Version of CancerLinQ™ Data Analytics Platform Debuts at Annual Meeting
ASCO’s wholly owned nonprofit subsidiary, CancerLinQ LLC, provided the first demonstration of its groundbreaking health information technology platform at the 2015 ASCO Annual Meeting in Chicago. Beginning May 30, demonstrations of the CancerLinQ platform’s initial components were...
ASCO 2015: ASCO Announces First-Ever Clinical Trial
ASCO announced its first-ever clinical trial, which will offer patients with advanced cancer access to molecularly targeted cancer drugs and collect “real-world” data on clinical outcomes, to help learn the best uses of these drugs outside of indications approved by the U.S. Food and...
Vismodegib Safety Profile in Long-Term ‘Real-World’ Use in Advanced Basal Cell Carcinoma
In a preplanned interim analysis of the international open-label STEVIE trial reported in The Lancet Oncology, Basset-Seguin et al have provided safety data and efficacy outcomes with the use of vismodegib (Erivedge) for 1 year in patients with advanced basal cell carcinoma. STEVIE was designed to...
